Compare BZH & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZH | APLT |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.0M | 18.0M |
| IPO Year | 1994 | 2019 |
| Metric | BZH | APLT |
|---|---|---|
| Price | $23.18 | $0.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $32.00 | $1.25 |
| AVG Volume (30 Days) | 408.6K | ★ 11.6M |
| Earning Date | 01-29-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $2,371,555,000.00 | $1,000,000.00 |
| Revenue This Year | $7.40 | $124.18 |
| Revenue Next Year | $12.09 | $25.00 |
| P/E Ratio | $15.64 | ★ N/A |
| Revenue Growth | ★ 1.77 | N/A |
| 52 Week Low | $17.37 | $0.09 |
| 52 Week High | $29.30 | $1.50 |
| Indicator | BZH | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 30.38 |
| Support Level | $23.52 | $0.10 |
| Resistance Level | $24.52 | $0.10 |
| Average True Range (ATR) | 0.83 | 0.01 |
| MACD | 0.36 | 0.02 |
| Stochastic Oscillator | 76.40 | 60.00 |
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in states and metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the sources of revenue for the company. Its segments involve: West segment that includes Arizona, California, Nevada, and Texas; East segment that includes Delaware, Indiana, Maryland, Tennessee, and Virginia; and Southeast segment which includes Florida, Georgia, North Carolina, and South Carolina.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.